ENTITY
HUTCHMED

HUTCHMED (HCM US)

56
Analysis
Health Care • Hong Kong
HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. The company has several novel oncology products marketed in China, with one also approved in the US, Europe, and Japan. HUTCHMED was founded in 2000 and is headquartered in Hong Kong.
more
bullish•HUTCHMED
•22 Apr 2020 14:51•Issuer-paid

Hutchison China MediTech - Fortune favours the brave

Notwithstanding the COVID-19 pandemic challenges, Hutchison China MediTech (HCM) remains on track for potential approval and launches of two...

Share
bullish•HUTCHMED
•24 Mar 2020 20:37•Issuer-paid

Hutchison China MediTech - From innovation to oncology commercialization

Hutchison China MediTech’s (HCM’s) investment case is focused on evolution into a global R&D and commercial-stage biopharma company with a...

Share
bullish•HUTCHMED
•23 Mar 2020 22:08•Issuer-paid

Hutchison China MediTech - From innovation to oncology commercialisation

Hutchison China MediTech’s (HCM’s) investment case is focused on evolution into a global R&D and commercial-stage biopharma company with a...

Share
•26 Jan 2020 11:42

ECM Weekly (26 Jan 2020) - Central Retail Corp, Smoore, Mindspace Biz Parks REIT, Elite Comm REIT

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Happy...

Share
bullish•HUTCHMED
•22 Jan 2020 18:02

Hutchison-China Meditech Placement: Catalysts to Expect but Keep Overhang in Mind

HCM, a leading China biotech company, filed a prospectus to sell USD 110 million of ADS. We have covered the company's fundamentals for its Hong...

Logo
654 Views
Share
x